Senti Biosciences Holdings Inc. (SNTI)
NASDAQ: SNTIHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SNTI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.02M
- EPS (TTM)
- -$1.70
- Dividend yield
- None
- 52-week range
- 0.29 – 2.88
- Day range
- 0.3133 – 0.3293
- Volume / Avg
- 247.16K / 573.78K
- Beta
- —
- Shares outstanding
- 31.15M
52-week range
SNTI stock today
On Oct 8, SNTI ended the session at $0.3217, shedding $0.0083 (2.52%), versus the S&P 500's 0.47% decline. Trading was light, with 247.16K shares changing hands, about 43% of the average daily volume. At this level, SNTI sits near the bottom of its 52-week range of $0.29 to $2.88: 88.8% below the high, set on Dec 9, 2025 and 10.9% above the low.
SNTI is down 69.1% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 81.9%. Senti Biosciences has posted a net loss over the last twelve months (EPS of -$1.70), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Senti Biosciences
Company profileSenti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Timothy K. Lu M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 39
- IPO year
- 2021
- Website
- sentibio.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$13.50+4096.46%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Senti Biosciences peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMMBChemomab Therapeutics Ltd. ADR | 1.39 | +2.21% | $10.19M | vs SNTI |
| TOVXTheriva Biologics Inc. | 0.2271 | -2.95% | $10.42M | vs SNTI |
| ADILAdial Pharmaceuticals Inc | 3.97 | -0.50% | $10.42M | vs SNTI |
| GTBPGT Biopharma Inc. | 5.96 | -3.87% | $10.75M | vs SNTI |
| VTGNVistagen Therapeutics Inc. | 0.2462 | -0.36% | $10.93M | vs SNTI |
| BLRXBioLineRx Ltd. ADR | 2.21 | +0.23% | $11.00M | vs SNTI |
| IMRNImmuron Limited ADR | 1.11 | +1.83% | $8.96M | vs SNTI |
| BIVIBioVie Inc. Class A | 1.28 | -8.57% | $11.11M | vs SNTI |
Indexes, lists and sector
Appears in lists
Senti Biosciences stock FAQ
What is Senti Biosciences's stock price today?
SNTI last traded at $0.3217 as of Oct 8, 4:00 PM EDT, down 2.52% on the day. Prices are delayed at least 15 minutes.
Does Senti Biosciences pay a dividend?
No. Senti Biosciences does not currently pay a regular cash dividend.
Who is Senti Biosciences's CEO?
Dr. Timothy K. Lu M.D., Ph.D. is the chief executive officer of Senti Biosciences Holdings Inc., which has about 39 employees.
Has SNTI ever split its stock?
Yes. The most recent SNTI stock split was a 1-for-10 split on Jul 18, 2024.
What is the SNTI 52-week high?
The 52-week high for SNTI is $2.88 and the 52-week low is $0.29. The stock is currently 88.8% below its high.